Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 54Neoplasms 47Colorectal Neoplasms 31Prostatic Neoplasms 27Carcinoma, Non-Small-Cell Lung 24Lung Neoplasms 21Leukemia, Myeloid, Acute 19Recurrence 12Stomach Neoplasms 11Multiple Myeloma 11Melanoma 11Head and Neck Neoplasms 10Squamous Cell Carcinoma of Head and Neck 9Ovarian Neoplasms 9Uterine Cervical Neoplasms 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Pancreatic Neoplasms 8Neoplasm Metastasis 8Myelodysplastic Syndromes 8Lymphoma, Non-Hodgkin 8Lymphoma 8Glioma 8Brain Neoplasms 8Motor Activity 7Esophageal Neoplasms 7Carcinoma, Renal Cell 7Carcinoma, Hepatocellular 7Leukemia 6Hodgkin Disease 6Colonic Neoplasms 6

Interventions

Taxes 1Platinum 1Paclitaxel 1Immunoglobulin G 1Disulfides 1Cisplatin 1Carboplatin 1Bevacizumab 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Brenner Tumor × 30 days × Clear all
NCT00951496 2026-06-02

Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

National Cancer Institute (NCI)

Phase 3 Completed
1,560 enrolled 19 charts

Brenner Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡